ProCE Banner Activity

ARAMIS Final Analysis: OS With Darolutamide Plus ADT vs Placebo Plus ADT for Nonmetastatic Castration-Resistant Prostate Cancer

Slideset Download
Conference Coverage
Darolutamide plus ADT led to 31% risk reduction of death vs placebo plus ADT and no new safety concerns upon longer follow-up.

Released: June 04, 2020

Expiration: June 03, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono